CANADIAN PATENTED DRUG PRICE REDUCTIONS OF UP TO 1.1%
CANADIAN PATENTED DRUG PRICE REDUCTIONS OF UP TO 1.1% effective in January "will be required in cases where companies are currently charging the maximum allowable prices," the Canadian Patented Medicine Prices Review Board reports in its July 1994 Bulletin. Prices for patented drags in Canada are indexed to inflation by the Consumer Price Index. "The most recent forecast of the Department of Finance is that the CPI will increase by 1.3% in 1995 over 1994," the Bulletin states. However, the 1995 forecast "is actually below" the forecast CPI for the current year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth